anandamide and Syndrome

anandamide has been researched along with Syndrome* in 2 studies

Trials

1 trial(s) available for anandamide and Syndrome

ArticleYear
Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome.
    Shock (Augusta, Ga.), 2004, Volume: 21, Issue:1

    Acute hypotension, hypoxemia, cardiac arrhythmias, cardiac arrest, (or a combination of these), and sudden death are well-recognized complications of the cemented hip arthroplasty procedure. Collectively, these are known as the bone cement implantation syndrome (BCIS). The endogenous cannabinoids, anandamide (ANA) and 2-arachidonylglycerol (2-AG), are reported to be strong vasodilators and play a role in the hypotension associated with hemorrhagic and septic shock. In the present study, a potential role for the endogenous cannabinoids in influencing hemodynamic variables in BCIS was investigated. Thirty-five patients (35 hips) entered a prospective, randomized clinical trial. The patients were divided into two groups. Group 1 comprised 16 patients who had the component inserted using a conventional cementing technique, whereas group 2 consisted of 19 patients who had the femoral component inserted without cement. Blood samples were taken at six consecutive time points: before anesthesia, after reaming the femur, 2 min after insertion of stems with or without cement into the femur, and 10 min, 20, and 30 min after stem insertion. In group 1 (with cement), the mean levels of ANA and 2-AG significantly increased after stem insertion. In a comparison of each group after stem insertion, mean ANA and 2-AG levels in group 1 also significantly differed from those in group 2. By contrast, in group 2 (without cement) neither ANA nor 2-AG levels exhibited a significant increase or change at any point in time. In conclusion, we have shown for the first time that endogenous cannabinoids are candidates for lipid mediators of BCIS.

    Topics: Aged; Arachidonic Acids; Arthroplasty, Replacement, Hip; Blood Pressure; Bone Cements; Cannabinoids; Endocannabinoids; Female; Glycerides; Heart Diseases; Humans; Hypotension; Lipid Metabolism; Male; Models, Biological; Polyunsaturated Alkamides; Prospective Studies; Prosthesis Failure; Shock; Syndrome; Time Factors; Vasodilator Agents

2004

Other Studies

1 other study(ies) available for anandamide and Syndrome

ArticleYear
Fetal Syndrome of Endocannabinoid Deficiency (FSECD) In Maternal Obesity.
    Medical hypotheses, 2016, Volume: 96

    The theory of a fetal origin of adult diseases links many pathological conditions to very early life events and is known as a "developmental programming" phenomenon. The mechanisms of this phenomenon are not quite understood and have been explained by inflammation, stress, etc. In particular the epidemic of obesity, with more than 64% of women being overweight or obese, has been associated with conditions in later life such as mental disorders, diabetes, asthma, and irritable bowel syndrome. Interestingly, these diseases were classified a decade ago as Clinical Syndrome of Endocannabinoid Deficiency (CECD), which was first described by Russo in 2004. Cannabinoids have been used for the treatment of chronic pain for millenniums and act through the mechanism of "kick-starting" the components of the endogenous cannabinoid system (ECS). ECS is a pharmacological target for the treatment of obesity, inflammation, cardiovascular and neuronal damage, and pain. We hypothesize that the deteriorating effect of maternal obesity on offspring health is explained by the mechanism of Fetal Syndrome of Endocannabinoid Deficiency (FSECD), which accompanies maternal obesity. Here we provide support for this hypothesis.

    Topics: Adult; Animals; Arachidonic Acids; Asthma; Autism Spectrum Disorder; Cannabinoids; Endocannabinoids; Female; Fetal Nutrition Disorders; Glycerides; Humans; Insulin Resistance; Irritable Bowel Syndrome; Models, Theoretical; Obesity; Phenotype; Polyunsaturated Alkamides; Pregnancy; Pregnancy Complications; Syndrome; Young Adult

2016